+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Erectile Dysfunction Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851893
  • Report
  • June 2018
  • Region: Global
  • 196 pages
  • Transparency Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

Erectile Dysfunction (ED) Drugs Market - Overview

This report studies the current as well as future prospects of the global erectile dysfunction (ED) drugs market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and marketing of therapeutic drugs for the treatment of erectile dysfunction, as well as new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global erectile dysfunction drugs market with respect to the leading segments based on drug class, distribution channel, and region.

The global erectile dysfunction drugs market has been segmented based on drug, distribution channel, and region. In terms of drug, the market has been classified into Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and others. Based on distribution channel, the global erectile dysfunction drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of erectile dysfunction. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the global erectile dysfunction drugs market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global erectile dysfunction drugs market.

Geographically, the global erectile dysfunction drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global erectile dysfunction drugs market.

Major players operating in the global erectile dysfunction drugs market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, VIVUS, Inc., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights

2. Assumptions and Research Methodology
2.1. Secondary Research Methodology
2.2. Primary Research Methodology
2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Definition
4.1.2. Industry Evolution/Developments
4.2. Overview

5. Market Outlook
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Opportunity Analysis
5.1.5. Trends
5.2. Global Erectile Dysfunction Market Analysis and Forecasts, 2016-2026
5.3. Porter’s Five Forces Analysis
5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
5.5. Pipeline Analysis
5.5.1. Discovery
5.5.2. Preclinical
5.5.3. IND (Investigational New Drug)
5.5.4. Phase I
5.5.5. Phase I/II
5.5.6. Phase II
5.5.7. Phase III
5.5.8. Pre-registration
5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Drug
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug, 2016-2026
6.3.1. Viagra
6.3.2. Cialis
6.3.3. Staxyn/Levitra
6.3.4. Stendra/Spedra
6.3.5. Others
6.4. Market Attractiveness, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2016-2026
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Market Attractiveness, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug, 2016-2026
9.2.1. Viagra
9.2.2. Cialis
9.2.3. Staxyn/Levitra
9.2.4. Stendra/Spedra
9.2.5. Others
9.3. Market Value Forecast, by Distribution Channel, 2016-2026
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug, 2016-2026
10.2.1. Viagra
10.2.2. Cialis
10.2.3. Staxyn/Levitra
10.2.4. Stendra/Spedra
10.2.5. Others
10.3. Market Value Forecast, by Distribution Channel, 2016-2026
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Drug, 2016-2026
11.2.1. Viagra
11.2.2. Cialis
11.2.3. Staxyn/Levitra
11.2.4. Stendra/Spedra
11.2.5. Others
11.3.Market Value Forecast, by Distribution Channel, 2016-2026
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4.Market Value Forecast, by Country/Sub-region, 2016-2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Drug, 2016-2026
12.2.1. Viagra
12.2.2. Cialis
12.2.3. Staxyn/Levitra
12.2.4. Stendra/Spedra
12.2.5. Others
12.3.Market Value Forecast, by Distribution Channel, 2016-2026
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4.Market Value Forecast, by Country/Sub-region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Drug, 2016-2026
13.2.1. Viagra
13.2.2. Cialis
13.2.3. Staxyn/Levitra
13.2.4. Stendra/Spedra
13.2.5. Others
13.3.Market Value Forecast, by Distribution Channel, 2016-2026
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4.Market Value Forecast, by Country/Sub-region, 2016-2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa

14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2017)
14.3. Competitive Business Strategies
14.4. Company Profiles
14.4.1. Pfizer, Inc.
14.4.1.1. Company Overview (HQ, Business Segments, Employee)
14.4.1.2. Product Portfolio
14.4.1.3. SWOT Analysis
14.4.1.4. Strategic Overview
14.4.2. Dong-A ST Co., Ltd.
14.4.2.1. Company Overview (HQ, Business Segments, Employee)
14.4.2.2. Product Portfolio
14.4.2.3. SWOT Analysis
14.4.2.4. Strategic Overview
14.4.3. Eli Lilly and Company
14.4.3.1. Company Overview (HQ, Business Segments, Employee)
14.4.3.2. Product Portfolio
14.4.3.3. SWOT Analysis
14.4.3.4. Strategic Overview
14.4.4. Bayer AG
14.4.4.1. Company Overview (HQ, Business Segments, Employee)
14.4.4.2. Product Portfolio
14.4.4.3. SWOT Analysis
14.4.4.4. Strategic Overview
14.4.5. VIVUS, INC.
14.4.5.1. Company Overview (HQ, Business Segments, Employee)
14.4.5.2. Product Portfolio
14.4.5.3. SWOT Analysis
14.4.5.4. Strategic Overview
14.4.6. SK chemicals
14.4.6.1. Company Overview (HQ, Business Segments, Employee)
14.4.6.2. Product Portfolio
14.4.6.3. SWOT Analysis
14.4.6.4. Strategic Overview
14.4.7. Meda Pharmaceuticals Inc.
14.4.7.1. Company Overview (HQ, Business Segments, Employee)
14.4.7.2. Product Portfolio
14.4.7.3. SWOT Analysis
14.4.7.4. Strategic Overview
14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
14.4.8.1. Company Overview (HQ, Business Segments, Employee)
14.4.8.2. Product Portfolio
14.4.8.3. SWOT Analysis
14.4.8.4. Strategic Overview
14.4.9. Apricus Biosciences, Inc.
14.4.9.1. Company Overview (HQ, Business Segments, Employee)
14.4.9.2. Product Portfolio
14.4.9.3. SWOT Analysis
14.4.9.4. Strategic Overview
14.4.10. Teva Pharmaceutical Industries Ltd.
14.4.10.1. Company Overview (HQ, Business Segments, Employee)
14.4.10.2. Product Portfolio
14.4.10.3. SWOT Analysis
14.4.10.4. Strategic Overview
Note: Product cover images may vary from those shown
Adroll
adroll